{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:42:55Z","timestamp":1772026975083,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"crossref","award":["H230885, H220142"],"award-info":[{"award-number":["H230885, H220142"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"crossref","award":["H230885, H220142"],"award-info":[{"award-number":["H230885, H220142"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04767-9","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:57:10Z","timestamp":1745456230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience"],"prefix":"10.1186","volume":"25","author":[{"given":"Shangsong","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zicheng","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"publisher","first-page":"716832","DOI":"10.3389\/fcvm.2021.716832","volume":"8","author":"D Neglia","year":"2021","unstructured":"Neglia D, Maroz-Vadalazhskaya N, Carrabba N, Liga R. Coronary revascularization in patients with stable coronary artery disease: the role of imaging. Front Cardiovasc Med. 2021;8:716832.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"4767_CR2","first-page":"179","volume":"17","author":"T W\u00f3jcik","year":"2021","unstructured":"W\u00f3jcik T, Karolko B, Wi\u015bniewski J, Mysiak A, \u015aciborski K, Onisk G, et al. The influence of acute coronary syndrome on levels of clopidogrel active metabolite and platelet Inhibition in patients with and without CYP2C19*2(681 G\u2009>\u2009A), *3(636 G\u2009>\u2009A) and ABCB1(C3435C\u2009>\u2009T) gene polymorphisms. Postepy Kardiol Interwencyjnej. 2021;17(2):179\u201386.","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"9","key":"4767_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.amjcard.2011.06.039","volume":"108","author":"S Friedland","year":"2011","unstructured":"Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2011;108(9):1244\u201351.","journal-title":"Am J Cardiol"},{"key":"4767_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ahj.2022.10.006","volume":"255","author":"A Oliva","year":"2023","unstructured":"Oliva A, Castiello DS, Franzone A, Condorelli G, Colombo A, Esposito G, et al. P2Y12 inhibitors monotherapy in patients undergoing complex vs Non-Complex percutaneous coronary intervention: A Meta-Analysis of randomized trials. Am Heart J. 2023;255:71\u201381.","journal-title":"Am Heart J"},{"issue":"2","key":"4767_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2459\/JCM.0000000000001399","volume":"24","author":"S De Servi","year":"2023","unstructured":"De Servi S, Landi A, Savonitto S, De Luca L, De Luca G, Morici N, et al. Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. J Cardiovasc Med (Hagerstown). 2023;24(2):77\u201386.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"4767_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ahj.2006.06.003","volume":"152","author":"CM Gibson","year":"2006","unstructured":"Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, et al. Early initiation of Eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the time to integrilin therapy in acute myocardial infarction (TITAN)-TIMI 34 trial. Am Heart J. 2006;152(4):668\u201375.","journal-title":"Am Heart J"},{"issue":"5","key":"4767_CR7","doi-asserted-by":"publisher","first-page":"e0232768","DOI":"10.1371\/journal.pone.0232768","volume":"15","author":"T Charpentier","year":"2020","unstructured":"Charpentier T, Ferdynus C, Lair T, Cordier C, Brulliard C, Valance D, et al. Bleeding risk of Ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis. PLoS ONE. 2020;15(5):e0232768.","journal-title":"PLoS ONE"},{"issue":"2","key":"4767_CR8","first-page":"485","volume":"33","author":"L Han","year":"2019","unstructured":"Han L, Zhang JJ, Jing HF, Qin L. Ticagrelor for patients with ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention. J Biol Regul Homeost Agents. 2019;33(2):485\u201390.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"2","key":"4767_CR9","doi-asserted-by":"publisher","first-page":"e0246166","DOI":"10.1371\/journal.pone.0246166","volume":"16","author":"ZJ Xie","year":"2021","unstructured":"Xie ZJ, Xin SL, Chang C, Zhou HJ, Zhao XF, Jiao FH, et al. Combined glycoprotein IIb\/IIIa inhibitor therapy with Ticagrelor for patients with acute coronary syndrome. PLoS ONE. 2021;16(2):e0246166.","journal-title":"PLoS ONE"},{"issue":"3","key":"4767_CR10","first-page":"80","volume":"44","author":"NA Gratsianskii","year":"2004","unstructured":"Gratsianskii NA. [Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need Abciximab infusion? Results of ISAR-REACT study]. Kardiologiia. 2004;44(3):80\u20131.","journal-title":"Kardiologiia"},{"key":"4767_CR11","doi-asserted-by":"crossref","unstructured":"Galli M, Andreotti F, Sabouret P, Gragnano F. 2023 ESC Guidelines on ACS: what is new in antithrombotic therapy? Eur Heart J Cardiovasc Pharmacother. 2023;9(7):595-6.","DOI":"10.1093\/ehjcvp\/pvad065"},{"issue":"2","key":"4767_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jebm.12253","volume":"10","author":"X Zhou","year":"2017","unstructured":"Zhou X, Wu X, Sun H, Li J. Efficacy and safety of Eptifibatide versus Tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis. J Evid Based Med. 2017;10(2):136\u201344.","journal-title":"J Evid Based Med"},{"key":"4767_CR13","doi-asserted-by":"publisher","first-page":"112196","DOI":"10.1016\/j.biopha.2021.112196","volume":"143","author":"X Hu","year":"2021","unstructured":"Hu X, Wang W, Ye J, Lin Y, Yu B, Zhou L, et al. Effect of GP IIb\/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-\/slow-reflow phenomenon. Biomed Pharmacother. 2021;143:112196.","journal-title":"Biomed Pharmacother"},{"issue":"4A","key":"4767_CR14","doi-asserted-by":"publisher","first-page":"B34","DOI":"10.1016\/S0002-9149(97)00575-4","volume":"80","author":"RA Harrington","year":"1997","unstructured":"Harrington RA. Design and methodology of the PURSUIT trial: evaluating Eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: receptor suppression using integrilin therapy. Am J Cardiol. 1997;80(4A):B34\u20138.","journal-title":"Am J Cardiol"},{"issue":"1","key":"4767_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ccd.21059","volume":"70","author":"JP Dery","year":"2007","unstructured":"Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, et al. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb\/IIIa integrin Blockade with Eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007;70(1):43\u201350.","journal-title":"Catheter Cardiovasc Interv"},{"key":"4767_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijcard.2017.01.007","volume":"232","author":"S Farhan","year":"2017","unstructured":"Farhan S, Clare RM, Jarai R, Giugliano RP, Lokhnygina Y, Harrington RA, et al. Fasting glucose, NT-proBNP, treatment with Eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. Int J Cardiol. 2017;232:264\u201370.","journal-title":"Int J Cardiol"},{"key":"4767_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2020.09.054","volume":"139","author":"F Fischer","year":"2021","unstructured":"Fischer F, Buxy S, Kurz DJ, Eberli FR, Senn O, Zbinden R, et al. Efficacy and safety of abbreviated Eptifibatide treatment in patients with ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2021;139:15\u201321.","journal-title":"Am J Cardiol"},{"issue":"3","key":"4767_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.25122\/jml-2021-0035","volume":"14","author":"R Jalalian","year":"2021","unstructured":"Jalalian R, Golshani S, Farsavian H, Vatani M, Farsavian AA. Efficacy of intravenous Eptifibatide in primary percutaneous coronary intervention patients. J Med Life. 2021;14(3):376\u201382.","journal-title":"J Med Life"},{"issue":"4","key":"4767_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s11239-021-02584-3","volume":"53","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu H. Efficacy outcomes and safety measures of intravenous Tirofiban or Eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies. J Thromb Thrombolysis. 2022;53(4):898\u2013910.","journal-title":"J Thromb Thrombolysis"},{"key":"4767_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2016.03.015","volume":"177","author":"YJ Shimada","year":"2016","unstructured":"Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, et al. Impact of glycoprotein IIb\/IIIa inhibitors on the efficacy and safety of Ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the platelet Inhibition and patient outcomes (PLATO) trial. Am Heart J. 2016;177:1\u20138.","journal-title":"Am Heart J"},{"issue":"13","key":"4767_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/eurheartj\/ehx799","volume":"39","author":"M Zeitouni","year":"2018","unstructured":"Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, et al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018;39(13):1100\u20139.","journal-title":"Eur Heart J"},{"issue":"4","key":"4767_CR22","first-page":"527","volume":"13","author":"L Manzi","year":"2024","unstructured":"Manzi L, Florimonte D, Forzano I, Buongiorno F, Sperandeo L, Castiello DS, et al. Antiplatelet therapy in patients requiring oral anticoagulation and undergoing percutaneous coronary intervention. Interv Cardiol Clin. 2024;13(4):527\u201341.","journal-title":"Interv Cardiol Clin"},{"key":"4767_CR23","first-page":"101344","volume":"50","author":"G Gargiulo","year":"2024","unstructured":"Gargiulo G, Cirillo P, Sperandeo L, Forzano I, Castiello DS, Florimonte D, et al. Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: pharmacodynamic data from the POMPEII study. Int J Cardiol Heart Vasc. 2024;50:101344.","journal-title":"Int J Cardiol Heart Vasc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04767-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:57:14Z","timestamp":1745456234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04767-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04767-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study procedure conformed to the ethical guidelines of the Declaration of Helsinki, and approval for the study was obtained from the Institutional Review Board of The First Affiliated Hospital of Soochow University (ethics approval no. 20190025001). Informed consent was obtained from all patients involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"312"}}